Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Immuneering (IMRX) Non Operating Investment Income (2021 - 2022)

Immuneering's Non Operating Investment Income history spans 2 years, with the latest figure at $112353.0 for Q4 2022.

  • On a quarterly basis, Non Operating Investment Income rose 353.86% to $112353.0 in Q4 2022 year-over-year; TTM through Dec 2022 was $18889.0, a N/A change, with the full-year FY2022 number at $18889.0, up 138.54% from a year prior.
  • Non Operating Investment Income came in at $112353.0 for Q4 2022, up from $39088.0 in the prior quarter.
  • The five-year high for Non Operating Investment Income was $112353.0 in Q4 2022, with the low at -$118386.0 in Q1 2022.